Loss of BAX in a neuroblastoma patient reveals delayed apoptosis but sustained chemotherapy sensitivity.
Neuroblastoma lacking one death protein retained chemotherapy sensitivity through alternative mechanisms, challenging assumptions about treatment resistance.
Molero-Valenzuela et al. characterise a neuroblastoma case with somatic BAX loss, finding that while canonical BAX-mediated apoptosis is impaired, chemotherapy sensitivity is retained through alternative non-BAX cell death mechanisms identified by comprehensive mechanistic analysis. Published in NPJ Precision Oncology, this challenges the assumption that BAX loss uniformly confers chemotherapy resistance in paediatric cancers and has direct implications for personalised treatment decision-making in BAX-deficient tumours.
What the study was
- Study design
- Single case report with comprehensive mechanistic analysis
- Population
- Paediatric neuroblastoma patient with somatic BAX loss
- Sample size
- 1
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- NPJ Precis Oncol
Why it surfaced
NPJ Precision Oncology mechanistic case study with implications for BAX-deficient neuroblastoma; open access; relevant to precision oncology and rare paediatric cancer.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.